Current State of the Development of Next-Generation Vaccines against Ebola Virus Disease

• Published in: Problemy osobo opasnyh infekcij no. 3; pp. 104 - 109
• Main Authors: Sizikova, T. E., Lebedev, V. N., Borisevich, S. V., Kutaev, D. A., Borisevich, I. V.
• Format: Journal Article
• Language: English; Russian
• Published: Federal Government Health Institution, Russian Research Anti-Plague Institute “Microbe” 20.09.2015
• Subjects: adenovirus; dna-vaccines; ebola virus; filoviruses; hemorrhagic fever; rna-replicons; specific prophylaxis; vector recombinant vaccines; vesicular stomatitis virus; virus-like particles; аденовирус; векторные рекомбинантные вакцины; вирус везикулярного стоматита; вирус эбола; вирусподобные частицы; днк-вакцины; рнк-репликоны; специфическая профилактика; филовирусы
• ISSN: 0370-1069; 2658-719X
• DOI: 10.21055/0370-1069-2015-3-104-109

Representative of Ebolavirus gender, Filoviridae family, Ebola virus is an etiological agent of particularly dangerous viral fever, the lethality of which comes up to 88 %. According to the leading specialists and experts in the sphere, vaccination is the most effective and cost-efficient method for the protection from epidemic spread. Objective of the review is to analyze current state of the development of next generation vaccines against Ebola fever. It is established that focus areas of the activities are the construction of vaccines on the basis of alpha-virus replicons, virus-like particles, and the development of DNA-vaccines and vector recombinant vaccines. The paper discusses the most significant achievements in the sphere of obtainment of potent therapies for prophylaxis as regards Ebola fever. To date manufactured, using various approaches, have been the next-generation vaccine preparations, for a number of which high protective capacity is demonstrated in the course of experiments on the nonhuman primates. The most advanced and prospective prototype is the vector recombinant vesicular stomatitis virus-based vaccine.